Fatal Anorexia caused by COVID-19 vaccination

A 90-year old woman weighting 40.5kg (89.3 pounds) develops anorexia after the first dose of the COVID-19 Pfizer vaccine (0.3 ml containing 30μg of mRNA).

Vital records showed abrupt increases in the body temperature, systolic and diastolic blood pressure, and pulse, and decreases in the intake of meals and drinks and body weight. The patient lost 1/4 of her body weight by the time of death 28 weeks after the COVID-19 vaccination. The patient also experienced hallucinations and decreased mental status, as well as decreased SpO2 levels. One month before death, her status was changed from level 2 (partial assistance) to level 5 (bedridden).  Before the injection her vitals were steady with exception of short-termed changes because of minor illnesses.

Vital records restricted to the last 6 months (180 days; Figure 2) show the pre-injection horizontal regression line, large + level change for temperature, pressures, and pulse, and – level change for meals and drinks, post-injection – regression line. The R-squared value (coefficient of determination) suggested that the injection strongly influenced and affected all the observed changes. 

The data were collected from April 2019 to August 2021 and included the day of the vaccine, 2 June 2021. The records include timetable records of three daily meals (shown as main dish 6/10, side dish 9/10, where 10/10 meant complete meal, while 0/10 meant no meal), drinks (ml), body temperature, blood pressure, pulse, saturation of percutaneous oxygen (SpO2), urination, defecation, and physical and medical examinations. 

READ MORE


REFERENCE

Osozawa S. Case Report: Anorexia as a new type of adverse reaction caused by the COVID-19 vaccination: a case report applying detailed personal care records. F1000Research. 2022 Jan 4;11(4):4.

Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

COVID in May

Image
Concerns about a potential resurgence of COVID-19 are mounting as summer 2024 approaches.  This is driven by several indicators, including social media posts, healthcare data, and wastewater surveillance across different regions. Our study findings corroborate this trend.  While many forecasters anticipate a surge, others expect a gradual increase through the end of May, and then a decline again around early June. Reports from social media suggest emerging clusters of COVID-19 in Texas, several Canadian provinces, the UK, and on cruises in northern regions such as a Norwegian cruise to Alaska.  Data from Alberta's Respiratory virus dashboard   (total weekly laboratory-confirmed COVID-19 cases) and wastewater surveillance in Calgary indicate an uptick in COVID-19 cases starting April 2024. The most recent statistics from Alberta Health reveal a significant increase in hospitalizations due to COVID-19, with 114 individuals currently hospitalized—an increase of more than 20% over two
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative (which happens quite often ). This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high viral load
Read more